Ligand Pharmaceuticals Inc., of San Diego, said partner Spectrum Pharmaceuticals Inc., of Henderson, Nev., submitted a new drug application to the FDA for Captisol-enabled melphalan for injection (propylene glycol-free) for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma.